Across TCGA pan-cancer cohorts, PHF2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PHF2 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PHF2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PHF2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where PHF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.577	0.182	.003	22	view →
HNSC	DFS	Median	IV	0.920	1.000	.028	9	view →
CCRCC	OS	Tertile	All	0.911	0.751	.018	7	view →
LSCC	DFS	Tertile	III,IV	1.000	0.550	.016	5	view →
OV	DFS	Quartile	All	0.612	0.884	.038	4	view →
GBM	OS	Median	All	0.479	0.300	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: PHF2 tumor-vs-normal RNA expression · all PHF2 data types